Elevated NAMPT expression levels were extensively reported in numerous solid and hematological malignancies, including pancreatic cancer [50], gastric cancer [71], prostate cancer [72], breast cancer [73,74], colorectal cancer [75,76,77], gliomas [78], ovarian cancer [79], melanoma [80], thyroid carcinoma [81], sarcomas [82], and lymphomas [83]. This evidence concerns the gene NAMPT and ovarian carcinoma.